Mercy Medical Center | GI Research
Status and phase
Conditions
Treatments
Study type
Funder types
Identifiers
About
A phase 2b, multicenter, randomized, double-blind, placebo-controlled study of HTD1801 in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
Full description
This phase 2b, double-blind, randomized, placebo-controlled, multicenter study will evaluate the effect of HTD1801, 1250 mg twice daily (BID) compared to placebo BID on histologic improvements in adult subjects with non-alcoholic steatohepatitis and liver fibrosis who have type 2 diabetes mellitus or pre-diabetes.
The study will enroll approximately 210 subjects with biopsy-confirmed non-alcoholic steatohepatitis and evidence of stage 2 or stage 3 liver fibrosis. Subjects will receive investigational product for up to 60 weeks.
Enrollment
Sex
Ages
Volunteers
Inclusion and exclusion criteria
Key Inclusion criteria:
Key Exclusion criteria:
Primary purpose
Allocation
Interventional model
Masking
218 participants in 2 patient groups, including a placebo group
Loading...
Central trial contact
Cathryn Bennett, BN, RN, CCRA
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal